Black Diamond Therapeutics Inc (BDTX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Black Diamond Therapeutics Inc (BDTX) has a cash flow conversion efficiency ratio of -0.062x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-7.85 Million) by net assets ($126.15 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Black Diamond Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how Black Diamond Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Black Diamond Therapeutics Inc debt and liabilities for a breakdown of total debt and financial obligations.
Black Diamond Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Black Diamond Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
RumbleON Inc
NASDAQ:RMBL
|
-2.319x |
|
SaltX Technology Holding AB
ST:SALT-B
|
-0.071x |
|
SENFONG
KLSE:5308
|
-0.163x |
|
China Electric Manufacturing Corp
TW:1611
|
0.012x |
|
Elementos Ltd
AU:ELT
|
-0.059x |
|
Indonesia Fibreboard Industry PT
JK:IFII
|
0.005x |
|
Traphaco JSC
VN:TRA
|
0.034x |
|
Afyon Cimento Sanayi TAS
IS:AFYON
|
-0.003x |
Annual Cash Flow Conversion Efficiency for Black Diamond Therapeutics Inc (2017–2024)
The table below shows the annual cash flow conversion efficiency of Black Diamond Therapeutics Inc from 2017 to 2024. For the full company profile with market capitalisation and key ratios, see how much is Black Diamond Therapeutics Inc worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $83.28 Million | $-62.30 Million | -0.748x | -30.89% |
| 2023-12-31 | $116.74 Million | $-66.72 Million | -0.572x | +22.28% |
| 2022-12-31 | $115.69 Million | $-85.08 Million | -0.735x | -43.85% |
| 2021-12-31 | $195.90 Million | $-100.15 Million | -0.511x | -201.71% |
| 2020-12-31 | $307.76 Million | $-52.15 Million | -0.169x | -132.38% |
| 2019-12-31 | $-47.16 Million | $-24.67 Million | 0.523x | -3.81% |
| 2018-12-31 | $-15.54 Million | $-8.45 Million | 0.544x | +54.44% |
| 2017-12-31 | $-6.67 Million | $-2.35 Million | 0.352x | -- |
About Black Diamond Therapeutics Inc
Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant n… Read more